Biopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
The biopharmaceuticals market is expected to grow from US$ 3,29,966.22 million in 2022 to US$ 7,00,873.94 million by 2028; it is expected to grow at a CAGR of 13.4% from 2022 to 2028.
Rising applications in cancer therapeutics and potential to treat rare diseases are a few factors driving the biopharmaceuticals market growth.
North America is likely to continue its dominance in the biopharmaceuticals market during the forecast period. The US held the largest market share in this region in 2022. According to The International Trade Administration report, the US is the largest market for biopharmaceuticals accounting for approximately a third of the global biopharmaceutical market with pioneers in biopharmaceutical R&D. Also, the economic impact of the biopharmaceutical industry in the US economy is substantial. In 2018, over US$ 17 billion in biopharmaceutical exports were from most foreign-owned firms operating in the US. Moreover, in the same year, these majority foreign-owned firms spent ~US$ 20 billion on R&D.
On the other hand, Asia Pacific is expected to witness lucrative growth over the forecast period. This is due to China's biopharmaceutical industry undergoing a tremendous shift evolving from a generics-focused to a thriving innovation hub. Additionally, promoting industrialization and growing application of novel drugs and high-end medical devices and techniques are a few factors responsible for the growth of the biopharmaceuticals market in China. For instance, in March 2022, CANbridge Pharmaceuticals Inc., a pioneer China-based biopharmaceutical company, announced that the Taiwan Food and Drug Administration (TFDA) had accepted the New Drug Application/Orphan Drug Registration (NDA/ODR) for 'CAN108 [maralixibat oral solution (LIVMARLI TM)]' intended for treating cholestatic pruritus among patients suffering from Alagille syndrome (ALGS) for 1 year of age and older. Such aforementioned factors are responsible for influential growth of biopharmaceuticals market in Asia Pacific during 2022-2028.
Market Opportunity
Accelerated Clinical Trials
Accelerated progress of clinical trials will ultimately result in the development and commercialization of new drugs targeting rare as well as common inherited diseases. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, acute leukemia that has been historically difficult to diagnose. Also, the disease is extremely rare—it impacts fewer than 1,000 patients in the US annually. In December 2018, Tagraxofusp became the first therapy approved for treating BPDCN, which then became the standard care method for treating these patients. During clinical trials, more than 90% of the patients who never received any treatment responded to therapy.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that weakens muscles, impacts physical function, and causes irreversible brain and spinal cord damage. To date, only 2 products are approved for slowing the functional decline associated with ALS. The accelerated clinical trials for developing new products targeting ALS are in progress. For example, antisense oligonucleotides (ASOs) have been showing promising results in clinical trials involving patients suffering from ALS. Further, different gene therapy approaches, targeting multiple mutations in patients for both sporadic ALS and familial ALS, are also in clinical trials.
Thus, an extensive pipeline of biopharmaceuticals that are in clinical trials is expected to offer lucrative growth opportunities to the biopharmaceuticals market in the coming years.
Based on product type, the biopharmaceuticals market is segmented into monooclonal antibodies, recombinant vaccines, conventional vaccine, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell and gene therapies, cytokines/interferon/interleukins, and others (mRNA-based therapeutics, etc.). The monoclonal antibodies segment held the largest market share in 2022 and is anticipated to register a significant CAGR during the forecast period. Monoclonal antibodies (mABs) are at the forefront of the biological products market and will continue to lead resource investment in the biopharmaceutical market by providing innovative therapeutic solutions intended for immune oncology and immunotherapy. mABs treat multiple diseases such as cancer, organ transplant rejection, inflammatory and autoimmune diseases, allergies, infections, COVID-19, osteoporosis, eye disorders, migraines, high cholesterol, and nervous system disorders. There are many different mABs used to treat cancer. They work in different ways to kill or stop cancer cells from growing. They all have names that include 'mab' at the end of their generic name—for example, trastuzumab (Herceptin) and rituximab (Mabthera). Approvals of monoclonal antibody therapies by the US Food and Drug Administration (FDA) have increased since the first drug containing monoclonal antibodies was approved for humans. A major benefit of monoclonal antibodies is that they have successfully been used to manufacture drugs to treat certain diseases, such as some cancers. Another benefit of monoclonal antibodies is that they are more accurate than other treatments. This improves effectiveness and can reduce some side effects. The quality of the monoclonal antibodies is standard for all production batches, which is important for both therapeutic use and diagnostics. Such aforementioned factors are responsible for the segment growth, thereby fueling the biopharmaceuticals market during the forecast period.
Based on application, the biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. The oncology segment held the largest share of the market in 2022; however, the inflammatory and infectious diseases segment is expected to register the highest CAGR during the forecast period. According to the National Institute of Health (NIH) report, cancer is a complex invasive genetic disease-causing significant mortality globally. For example, protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. Further, various top companies entered a research collaboration for developing novel therapeutics-based targeted protein-based technology for cancer treatment. For instance, in April 2022, Ubix Therapeutics announced a collaboration with SK Biopharmaceuticals to develop new compounds and medicines through Ubix's Degraducer technology for cancer treatment. Such aforementioned factors are responsible for the segment growth, thereby contributing to the market growth of biopharmaceuticals during the forecast period.
Food and Drug Administration, Japan External Trade Organization, Saudi Food and Drug Authority (SFDA), and American Hospital Association (AHA) are the primary and secondary sources referred to while preparing the report on the biopharmaceuticals market.
Rising applications in cancer therapeutics and potential to treat rare diseases are a few factors driving the biopharmaceuticals market growth.
North America is likely to continue its dominance in the biopharmaceuticals market during the forecast period. The US held the largest market share in this region in 2022. According to The International Trade Administration report, the US is the largest market for biopharmaceuticals accounting for approximately a third of the global biopharmaceutical market with pioneers in biopharmaceutical R&D. Also, the economic impact of the biopharmaceutical industry in the US economy is substantial. In 2018, over US$ 17 billion in biopharmaceutical exports were from most foreign-owned firms operating in the US. Moreover, in the same year, these majority foreign-owned firms spent ~US$ 20 billion on R&D.
On the other hand, Asia Pacific is expected to witness lucrative growth over the forecast period. This is due to China's biopharmaceutical industry undergoing a tremendous shift evolving from a generics-focused to a thriving innovation hub. Additionally, promoting industrialization and growing application of novel drugs and high-end medical devices and techniques are a few factors responsible for the growth of the biopharmaceuticals market in China. For instance, in March 2022, CANbridge Pharmaceuticals Inc., a pioneer China-based biopharmaceutical company, announced that the Taiwan Food and Drug Administration (TFDA) had accepted the New Drug Application/Orphan Drug Registration (NDA/ODR) for 'CAN108 [maralixibat oral solution (LIVMARLI TM)]' intended for treating cholestatic pruritus among patients suffering from Alagille syndrome (ALGS) for 1 year of age and older. Such aforementioned factors are responsible for influential growth of biopharmaceuticals market in Asia Pacific during 2022-2028.
Market Opportunity
Accelerated Clinical Trials
Accelerated progress of clinical trials will ultimately result in the development and commercialization of new drugs targeting rare as well as common inherited diseases. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, acute leukemia that has been historically difficult to diagnose. Also, the disease is extremely rare—it impacts fewer than 1,000 patients in the US annually. In December 2018, Tagraxofusp became the first therapy approved for treating BPDCN, which then became the standard care method for treating these patients. During clinical trials, more than 90% of the patients who never received any treatment responded to therapy.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that weakens muscles, impacts physical function, and causes irreversible brain and spinal cord damage. To date, only 2 products are approved for slowing the functional decline associated with ALS. The accelerated clinical trials for developing new products targeting ALS are in progress. For example, antisense oligonucleotides (ASOs) have been showing promising results in clinical trials involving patients suffering from ALS. Further, different gene therapy approaches, targeting multiple mutations in patients for both sporadic ALS and familial ALS, are also in clinical trials.
Thus, an extensive pipeline of biopharmaceuticals that are in clinical trials is expected to offer lucrative growth opportunities to the biopharmaceuticals market in the coming years.
Based on product type, the biopharmaceuticals market is segmented into monooclonal antibodies, recombinant vaccines, conventional vaccine, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell and gene therapies, cytokines/interferon/interleukins, and others (mRNA-based therapeutics, etc.). The monoclonal antibodies segment held the largest market share in 2022 and is anticipated to register a significant CAGR during the forecast period. Monoclonal antibodies (mABs) are at the forefront of the biological products market and will continue to lead resource investment in the biopharmaceutical market by providing innovative therapeutic solutions intended for immune oncology and immunotherapy. mABs treat multiple diseases such as cancer, organ transplant rejection, inflammatory and autoimmune diseases, allergies, infections, COVID-19, osteoporosis, eye disorders, migraines, high cholesterol, and nervous system disorders. There are many different mABs used to treat cancer. They work in different ways to kill or stop cancer cells from growing. They all have names that include 'mab' at the end of their generic name—for example, trastuzumab (Herceptin) and rituximab (Mabthera). Approvals of monoclonal antibody therapies by the US Food and Drug Administration (FDA) have increased since the first drug containing monoclonal antibodies was approved for humans. A major benefit of monoclonal antibodies is that they have successfully been used to manufacture drugs to treat certain diseases, such as some cancers. Another benefit of monoclonal antibodies is that they are more accurate than other treatments. This improves effectiveness and can reduce some side effects. The quality of the monoclonal antibodies is standard for all production batches, which is important for both therapeutic use and diagnostics. Such aforementioned factors are responsible for the segment growth, thereby fueling the biopharmaceuticals market during the forecast period.
Based on application, the biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. The oncology segment held the largest share of the market in 2022; however, the inflammatory and infectious diseases segment is expected to register the highest CAGR during the forecast period. According to the National Institute of Health (NIH) report, cancer is a complex invasive genetic disease-causing significant mortality globally. For example, protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. Further, various top companies entered a research collaboration for developing novel therapeutics-based targeted protein-based technology for cancer treatment. For instance, in April 2022, Ubix Therapeutics announced a collaboration with SK Biopharmaceuticals to develop new compounds and medicines through Ubix's Degraducer technology for cancer treatment. Such aforementioned factors are responsible for the segment growth, thereby contributing to the market growth of biopharmaceuticals during the forecast period.
Food and Drug Administration, Japan External Trade Organization, Saudi Food and Drug Authority (SFDA), and American Hospital Association (AHA) are the primary and secondary sources referred to while preparing the report on the biopharmaceuticals market.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Biopharmaceuticals Market – by Product Type
1.3.2 Global Biopharmaceuticals Market – by Application
1.3.3 Global Biopharmaceuticals Market – by Geography
2. BIOPHARMACEUTICALS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. BIOPHARMACEUTICALS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East & Africa PEST Analysis
4.2.5 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. BIOPHARMACEUTICALS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Rising Application in Cancer Therapeutics
5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
5.3.1 Accelerated Clinical Trials
5.4 Future Trends
5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis
6. BIOPHARMACEUTICALS MARKET – GLOBAL ANALYSIS
6.1 Global Biopharmaceuticals Market Revenue Forecast and Analysis
6.2 Global Biopharmaceuticals Market, by Geography – Forecast and Analysis
6.3 Market Positioning of Key Players
7. GLOBAL BIOPHARMACEUTICALS MARKET – REVENUE AND FORECAST TO 2028 – BY PRODUCT TYPE
7.1 Overview
7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
7.3.1 Overview
7.3.2 Monoclonal Antibodies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
7.4.1 Overview
7.4.2 Recombinant Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Cancer Vaccine
7.4.2.1.1 Overview
7.4.2.1.2 Cancer Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Malaria Vaccine
7.4.2.2.1 Overview
7.4.2.2.2 Malaria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Ebola Vaccine
7.4.2.3.1 Overview
7.4.2.3.2 Ebola Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Hepatitis-B Vaccine
7.4.2.4.1 Overview
7.4.2.4.2 Hepatitis-B Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.5 Tetanus Vaccine
7.4.2.5.1 Overview
7.4.2.5.2 Tetanus Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.6 Diphtheria Vaccine
7.4.2.6.1 Overview
7.4.2.6.2 Diphtheria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.7 Cholera Vaccine
7.4.2.7.1 Overview
7.4.2.7.2 Cholera Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.8 Others
7.4.2.8.1 Overview
7.4.2.8.2 Others: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
7.5.1 Overview
7.5.2 Conventional Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Polio Vaccine
7.5.2.1.1 Overview
7.5.2.1.2 Polio Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Pox Vaccine
7.5.2.2.1 Overview
7.5.2.2.2 Pox Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Other Conventional Vaccine
7.5.2.3.1 Overview
7.5.2.3.2 Other Conventional Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
7.6.1 Overview
7.6.2 Recombinant Growth Factors: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 Erythropoietin
7.6.2.1.1 Overview
7.6.2.1.2 Erythropoietin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Granulocyte Colony Stimulating Factor
7.6.2.2.1 Overview
7.6.2.2.2 Granulocyte Colony Stimulating Factor: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
7.7.1 Overview
7.7.2 Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Leukemia Inhibitory Factor (LIF)
7.7.2.1.1 Overview
7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 P53 Protein
7.7.2.2.1 Overview
7.7.2.2.2 P53 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.3 P38 Protein
7.7.2.3.1 Overview
7.7.2.3.2 P38 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.4 Other Purified Proteins
7.7.2.4.1 Overview
7.7.2.4.2 Other Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
7.8.1 Overview
7.8.2 Recombinant Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.1 Serum Albumin
7.8.2.1.1 Overview
7.8.2.1.2 Serum Albumin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.2 Amyloid Protein
7.8.2.2.1 Overview
7.8.2.2.2 Amyloid Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.3 Defensin
7.8.2.3.1 Overview
7.8.2.3.2 Defensin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.4 Transferrin
7.8.2.4.1 Overview
7.8.2.4.2 Transferrin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
7.9.1 Overview
7.9.2 Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.1 Recombinant Human Growth Hormones
7.9.2.1.1 Overview
7.9.2.1.2 Recombinant Human Growth Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.2 Recombinant Insulin
7.9.2.2.1 Overview
7.9.2.2.2 Recombinant Insulin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.3 Other Recombinant Hormones
7.9.2.3.1 Overview
7.9.2.3.2 Other Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
7.10.1 Overview
7.10.2 Recombinant Enzymes: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.1 Enterokinase
7.10.2.1.1 Overview
7.10.2.1.2 Enterokinase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.2 Cyclase
7.10.2.2.1 Overview
7.10.2.2.2 Cyclase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.3 Caspase
7.10.2.3.1 Overview
7.10.2.3.2 Caspase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.4 Cathepsin
7.10.2.4.1 Overview
7.10.2.4.2 Cathepsin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
7.11.1 Overview
7.11.2 Cell and Gene Therapies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.1 Allogenic Products
7.11.2.1.1 Overview
7.11.2.1.2 Allogenic Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.2 Autologous Products
7.11.2.2.1 Overview
7.11.2.2.2 Autologous Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.3 Acellular Products
7.11.2.3.1 Overview
7.11.2.3.2 Acellular Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
7.12.1 Overview
7.12.2 Cytokines/Interferon/Interleukins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
7.13.1 Overview
7.13.2 Others (mRNA Based Therapeutics, etc.): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. GLOBAL BIOPHARMACEUTICALS MARKET ANALYSIS AND FORECASTS TO 2028 – BY APPLICATION
8.1 Overview
8.2 Global Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
8.4.1 Overview
8.4.2 Inflammatory and Infectious Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Autoimmune Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolic Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
8.7.1 Overview
8.7.2 Hormonal Disorders and Growth Failure: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
8.8.1 Overview
8.8.2 Cardiovascular Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
8.9.1 Overview
8.9.2 Neurological Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
8.10.1 Overview
8.10.2 Other Therapeutic Applications: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. BIOPHARMACEUTICALS MARKET – REVENUE AND FORECAST TO 2028 – GEOGRAPHIC ANALYSIS
9.1 North America: Biopharmaceuticals Market
9.1.1 Overview
9.1.2 North America: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.3.1 North America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.3.2 North America: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.3.3 North America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.3.4 North America: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.3.5 North America: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.3.6 North America: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.3.7 North America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.3.8 North America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4 North America: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.1 United States: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.1.2 United States: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.2 Canada: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.2.2 Canada: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.3 Mexico: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2 Europe: Biopharmaceuticals Market
9.2.1 Overview
9.2.2 Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.3.1 Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.3.2 Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.3.3 Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.3.4 Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.3.5 Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.3.6 Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.3.7 Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.3.8 Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.4 Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5 Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.2.5.1 United Kingdom: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 United Kingdom: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.1.1.1 United Kingdom: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.1.1.2 United Kingdom: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.1.1.3 United Kingdom: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.1.1.4 United Kingdom: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.1.1.5 United Kingdom: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.1.1.6 United Kingdom: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.1.1.7 United Kingdom: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.1.1.8 United Kingdom: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.1.2 United Kingdom: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.2 Germany: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Germany: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.2.1.1 Germany: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.2.1.2 Germany: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.2.1.3 Germany: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.2.1.4 Germany: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.2.1.5 Germany: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.2.1.6 Germany: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.2.1.7 Germany: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.2.1.8 Germany: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.2.2 Germany: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.3 France: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 France: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.3.1.1 France: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.3.1.2 France: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.3.1.3 France: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.3.1.4 France: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.3.1.5 France: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.3.1.6 France: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.3.1.7 France: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.3.1.8 France: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.3.2 France: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.4 Italy: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Italy: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.4.1.1 Italy: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.4.1.2 Italy: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.4.1.3 Italy: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.4.1.4 Italy: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.4.1.5 Italy: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.4.1.6 Italy: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.4.1.7 Italy: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.4.1.8 Italy: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.4.2 Italy: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.5 Spain: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Spain: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.5.1.1 Spain: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.5.1.2 Spain: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.5.1.3 Spain: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.5.1.4 Spain: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.5.1.5 Spain: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.5.1.6 Spain: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.5.1.7 Spain: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.5.1.8 Spain: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.5.2 Spain: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.6 Rest of Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Rest of Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.6.1.1 Rest of Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.6.1.2 Rest of Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.6.1.3 Rest of Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.6.1.4 Rest of Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.6.1.5 Rest of Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.6.1.6 Rest of Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.6.1.7 Rest of Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.6.1.8 Rest of Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.6.2 Rest of Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3 Asia Pacific: Biopharmaceuticals Market
9.3.1 Overview
9.3.2 Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.3 Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.3.1 Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.3.2 Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.3.3 Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.3.4 Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.3.5 Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.3.6 Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.3.7 Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.3.8 Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.4 Asia Pacific: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5 Asia Pacific: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.3.5.1 China: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.1.1 China: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.1.1.1 China: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.1.1.2 China: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.1.1.3 China: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.1.1.4 China: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.1.1.5 China: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.1.1.6 China: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.1.1.7 China: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.1.1.8 China: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.1.2 China: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.2 Japan: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.2.1 Japan: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.2.1.1 Japan: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.2.1.2 Japan: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.2.1.3 Japan: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.2.1.4 Japan: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.2.1.5 Japan: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.2.1.6 Japan: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.2.1.7 Japan: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.2.1.8 Japan: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.2.2 Japan: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.3 India: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.3.1 India: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.3.1.1 India: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.3.1.2 India: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.3.1.3 India: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.3.1.4 India: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.3.1.5 India: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.3.1.6 India: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.3.1.7 India: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.3.1.8 India: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.3.2 India: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.4 South Korea: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.4.1 South Korea: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.4.1.1 South Korea: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.4.1.2 South Korea: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.4.1.3 South Korea: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.4.1.4 South Korea: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.4.1.5 South Korea: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.4.1.6 South Korea: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.4.1.7 South Korea: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.4.1.8 South Korea: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.4.2 South Korea: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.5 Australia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.5.1 Australia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.5.1.1 Australia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.5.1.2 Australia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.5.1.3 Australia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.5.1.4 Australia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.5.1.5 Australia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.5.1.6 Australia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.5.1.7 Australia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.5.1.8 Australia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.5.2 Australia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.6.1.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.6.1.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.6.1.3 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.6.1.4 Rest of Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.6.1.5 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.6.1.6 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.6.1.7 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.6.1.8 Rest of Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.6.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4 Middle East & Africa Biopharmaceuticals Market
9.4.1 Overview
9.4.2 Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.3 Middle East & Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.3.1 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.3.2 Middle East & Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.3.3 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.3.4 Middle East & Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.3.5 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.3.6 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.3.7 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.3.8 Middle East & Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.4 Middle East & Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5 Middle East & Africa: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.4.5.1 UAE: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.1.1 UAE: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.1.1.1 UAE: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.1.1.2 UAE: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.1.1.3 UAE: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.1.1.4 UAE: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.1.1.5 UAE: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.1.1.6 UAE: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.1.1.7 UAE: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.1.1.8 UAE: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.1.2 UAE: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.2 Saudi Arabia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.2.1 Saudi Arabia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.2.1.1 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.2.1.2 Saudi Arabia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.2.1.3 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.2.1.4 Saudi Arabia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.2.1.5 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.2.1.6 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.2.1.7 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.2.1.8 Saudi Arabia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.2.2 Saudi Arabia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.3 South Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.3.1 South Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.3.1.1 South Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.3.1.2 South Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.3.1.3 S
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Biopharmaceuticals Market – by Product Type
1.3.2 Global Biopharmaceuticals Market – by Application
1.3.3 Global Biopharmaceuticals Market – by Geography
2. BIOPHARMACEUTICALS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. BIOPHARMACEUTICALS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East & Africa PEST Analysis
4.2.5 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. BIOPHARMACEUTICALS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Rising Application in Cancer Therapeutics
5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
5.3.1 Accelerated Clinical Trials
5.4 Future Trends
5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis
6. BIOPHARMACEUTICALS MARKET – GLOBAL ANALYSIS
6.1 Global Biopharmaceuticals Market Revenue Forecast and Analysis
6.2 Global Biopharmaceuticals Market, by Geography – Forecast and Analysis
6.3 Market Positioning of Key Players
7. GLOBAL BIOPHARMACEUTICALS MARKET – REVENUE AND FORECAST TO 2028 – BY PRODUCT TYPE
7.1 Overview
7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
7.3.1 Overview
7.3.2 Monoclonal Antibodies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
7.4.1 Overview
7.4.2 Recombinant Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Cancer Vaccine
7.4.2.1.1 Overview
7.4.2.1.2 Cancer Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Malaria Vaccine
7.4.2.2.1 Overview
7.4.2.2.2 Malaria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Ebola Vaccine
7.4.2.3.1 Overview
7.4.2.3.2 Ebola Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Hepatitis-B Vaccine
7.4.2.4.1 Overview
7.4.2.4.2 Hepatitis-B Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.5 Tetanus Vaccine
7.4.2.5.1 Overview
7.4.2.5.2 Tetanus Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.6 Diphtheria Vaccine
7.4.2.6.1 Overview
7.4.2.6.2 Diphtheria Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.7 Cholera Vaccine
7.4.2.7.1 Overview
7.4.2.7.2 Cholera Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.8 Others
7.4.2.8.1 Overview
7.4.2.8.2 Others: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
7.5.1 Overview
7.5.2 Conventional Vaccines: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Polio Vaccine
7.5.2.1.1 Overview
7.5.2.1.2 Polio Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Pox Vaccine
7.5.2.2.1 Overview
7.5.2.2.2 Pox Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Other Conventional Vaccine
7.5.2.3.1 Overview
7.5.2.3.2 Other Conventional Vaccine: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
7.6.1 Overview
7.6.2 Recombinant Growth Factors: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 Erythropoietin
7.6.2.1.1 Overview
7.6.2.1.2 Erythropoietin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Granulocyte Colony Stimulating Factor
7.6.2.2.1 Overview
7.6.2.2.2 Granulocyte Colony Stimulating Factor: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
7.7.1 Overview
7.7.2 Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Leukemia Inhibitory Factor (LIF)
7.7.2.1.1 Overview
7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 P53 Protein
7.7.2.2.1 Overview
7.7.2.2.2 P53 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.3 P38 Protein
7.7.2.3.1 Overview
7.7.2.3.2 P38 Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.4 Other Purified Proteins
7.7.2.4.1 Overview
7.7.2.4.2 Other Purified Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
7.8.1 Overview
7.8.2 Recombinant Proteins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.1 Serum Albumin
7.8.2.1.1 Overview
7.8.2.1.2 Serum Albumin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.2 Amyloid Protein
7.8.2.2.1 Overview
7.8.2.2.2 Amyloid Protein: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.3 Defensin
7.8.2.3.1 Overview
7.8.2.3.2 Defensin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.8.2.4 Transferrin
7.8.2.4.1 Overview
7.8.2.4.2 Transferrin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
7.9.1 Overview
7.9.2 Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.1 Recombinant Human Growth Hormones
7.9.2.1.1 Overview
7.9.2.1.2 Recombinant Human Growth Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.2 Recombinant Insulin
7.9.2.2.1 Overview
7.9.2.2.2 Recombinant Insulin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.9.2.3 Other Recombinant Hormones
7.9.2.3.1 Overview
7.9.2.3.2 Other Recombinant Hormones: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
7.10.1 Overview
7.10.2 Recombinant Enzymes: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.1 Enterokinase
7.10.2.1.1 Overview
7.10.2.1.2 Enterokinase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.2 Cyclase
7.10.2.2.1 Overview
7.10.2.2.2 Cyclase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.3 Caspase
7.10.2.3.1 Overview
7.10.2.3.2 Caspase: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.10.2.4 Cathepsin
7.10.2.4.1 Overview
7.10.2.4.2 Cathepsin: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
7.11.1 Overview
7.11.2 Cell and Gene Therapies: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.1 Allogenic Products
7.11.2.1.1 Overview
7.11.2.1.2 Allogenic Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.2 Autologous Products
7.11.2.2.1 Overview
7.11.2.2.2 Autologous Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.11.2.3 Acellular Products
7.11.2.3.1 Overview
7.11.2.3.2 Acellular Products: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
7.12.1 Overview
7.12.2 Cytokines/Interferon/Interleukins: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
7.13.1 Overview
7.13.2 Others (mRNA Based Therapeutics, etc.): Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. GLOBAL BIOPHARMACEUTICALS MARKET ANALYSIS AND FORECASTS TO 2028 – BY APPLICATION
8.1 Overview
8.2 Global Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
8.4.1 Overview
8.4.2 Inflammatory and Infectious Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Autoimmune Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolic Disorders: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
8.7.1 Overview
8.7.2 Hormonal Disorders and Growth Failure: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
8.8.1 Overview
8.8.2 Cardiovascular Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
8.9.1 Overview
8.9.2 Neurological Diseases: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
8.10.1 Overview
8.10.2 Other Therapeutic Applications: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. BIOPHARMACEUTICALS MARKET – REVENUE AND FORECAST TO 2028 – GEOGRAPHIC ANALYSIS
9.1 North America: Biopharmaceuticals Market
9.1.1 Overview
9.1.2 North America: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.3.1 North America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.3.2 North America: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.3.3 North America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.3.4 North America: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.3.5 North America: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.3.6 North America: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.3.7 North America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.3.8 North America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4 North America: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.1 United States: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.1.2 United States: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.2 Canada: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.2.2 Canada: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.1.4.3 Mexico: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.1.4.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.1.4.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.1.4.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.1.4.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.1.4.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.1.4.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.1.4.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.1.4.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.1.4.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.1.4.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2 Europe: Biopharmaceuticals Market
9.2.1 Overview
9.2.2 Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.3.1 Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.3.2 Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.3.3 Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.3.4 Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.3.5 Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.3.6 Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.3.7 Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.3.8 Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.4 Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5 Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.2.5.1 United Kingdom: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 United Kingdom: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.1.1.1 United Kingdom: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.1.1.2 United Kingdom: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.1.1.3 United Kingdom: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.1.1.4 United Kingdom: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.1.1.5 United Kingdom: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.1.1.6 United Kingdom: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.1.1.7 United Kingdom: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.1.1.8 United Kingdom: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.1.2 United Kingdom: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.2 Germany: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 Germany: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.2.1.1 Germany: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.2.1.2 Germany: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.2.1.3 Germany: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.2.1.4 Germany: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.2.1.5 Germany: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.2.1.6 Germany: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.2.1.7 Germany: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.2.1.8 Germany: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.2.2 Germany: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.3 France: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 France: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.3.1.1 France: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.3.1.2 France: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.3.1.3 France: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.3.1.4 France: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.3.1.5 France: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.3.1.6 France: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.3.1.7 France: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.3.1.8 France: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.3.2 France: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.4 Italy: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Italy: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.4.1.1 Italy: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.4.1.2 Italy: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.4.1.3 Italy: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.4.1.4 Italy: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.4.1.5 Italy: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.4.1.6 Italy: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.4.1.7 Italy: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.4.1.8 Italy: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.4.2 Italy: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.5 Spain: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Spain: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.5.1.1 Spain: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.5.1.2 Spain: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.5.1.3 Spain: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.5.1.4 Spain: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.5.1.5 Spain: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.5.1.6 Spain: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.5.1.7 Spain: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.5.1.8 Spain: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.5.2 Spain: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.2.5.6 Rest of Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Rest of Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.2.5.6.1.1 Rest of Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.2.5.6.1.2 Rest of Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.2.5.6.1.3 Rest of Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.2.5.6.1.4 Rest of Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.2.5.6.1.5 Rest of Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.2.5.6.1.6 Rest of Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.2.5.6.1.7 Rest of Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.2.5.6.1.8 Rest of Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.2.5.6.2 Rest of Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3 Asia Pacific: Biopharmaceuticals Market
9.3.1 Overview
9.3.2 Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.3 Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.3.1 Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.3.2 Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.3.3 Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.3.4 Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.3.5 Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.3.6 Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.3.7 Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.3.8 Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.4 Asia Pacific: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5 Asia Pacific: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.3.5.1 China: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.1.1 China: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.1.1.1 China: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.1.1.2 China: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.1.1.3 China: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.1.1.4 China: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.1.1.5 China: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.1.1.6 China: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.1.1.7 China: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.1.1.8 China: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.1.2 China: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.2 Japan: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.2.1 Japan: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.2.1.1 Japan: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.2.1.2 Japan: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.2.1.3 Japan: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.2.1.4 Japan: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.2.1.5 Japan: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.2.1.6 Japan: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.2.1.7 Japan: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.2.1.8 Japan: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.2.2 Japan: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.3 India: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.3.1 India: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.3.1.1 India: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.3.1.2 India: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.3.1.3 India: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.3.1.4 India: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.3.1.5 India: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.3.1.6 India: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.3.1.7 India: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.3.1.8 India: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.3.2 India: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.4 South Korea: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.4.1 South Korea: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.4.1.1 South Korea: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.4.1.2 South Korea: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.4.1.3 South Korea: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.4.1.4 South Korea: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.4.1.5 South Korea: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.4.1.6 South Korea: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.4.1.7 South Korea: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.4.1.8 South Korea: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.4.2 South Korea: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.5 Australia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.5.1 Australia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.5.1.1 Australia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.5.1.2 Australia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.5.1.3 Australia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.5.1.4 Australia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.5.1.5 Australia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.5.1.6 Australia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.5.1.7 Australia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.5.1.8 Australia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.5.2 Australia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.3.5.6 Rest of Asia Pacific: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.3.5.6.1.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.3.5.6.1.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.3.5.6.1.3 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.3.5.6.1.4 Rest of Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.3.5.6.1.5 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.3.5.6.1.6 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.3.5.6.1.7 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.3.5.6.1.8 Rest of Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.3.5.6.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4 Middle East & Africa Biopharmaceuticals Market
9.4.1 Overview
9.4.2 Middle East & Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.3 Middle East & Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.3.1 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.3.2 Middle East & Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.3.3 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.3.4 Middle East & Africa: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.3.5 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.3.6 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.3.7 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.3.8 Middle East & Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.4 Middle East & Africa: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5 Middle East & Africa: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.4.5.1 UAE: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.1.1 UAE: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.1.1.1 UAE: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.1.1.2 UAE: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.1.1.3 UAE: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.1.1.4 UAE: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.1.1.5 UAE: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.1.1.6 UAE: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.1.1.7 UAE: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.1.1.8 UAE: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.1.2 UAE: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.2 Saudi Arabia: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.2.1 Saudi Arabia: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.2.1.1 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.2.1.2 Saudi Arabia: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.2.1.3 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)
9.4.5.2.1.4 Saudi Arabia: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)
9.4.5.2.1.5 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)
9.4.5.2.1.6 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)
9.4.5.2.1.7 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)
9.4.5.2.1.8 Saudi Arabia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)
9.4.5.2.2 Saudi Arabia: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)
9.4.5.3 South Africa: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4.5.3.1 South Africa: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)
9.4.5.3.1.1 South Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)
9.4.5.3.1.2 South Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)
9.4.5.3.1.3 S
